EUVIMEDOpdag EUVIMED
Multizentrische StudieVergleichsstudie

Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan

Shintaro Akiyama iD, Hiromichi Shimizu, Akiko Tamura, Kaoru Yokoyama, Toshiyuki Sakurai iD, Mariko Kobayashi, Makoto Eizuka, Shunichi Yanai iD, Kei Nomura, Tomoyoshi Shibuya, Masahiro Takahara, Sakiko Hiraoka and 11 more

Alimentary Pharmacology & Therapeutics · 2025-02 · 61 (3) · 524-537

DOI: 10.1111/apt.18406 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, published online on 2024-11-22. Written by Shintaro Akiyama and 22 co-authors. Institution: Department of Gastroenterology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan. Major MEDLINE topics: Colitis, Ulcerative, Janus Kinase Inhibitors, Piperidines, Pyrimidines. Cited 47 times so far (Crossref); 39 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Three Janus kinase (JAK) inhibitors are approved for ulcerative colitis (UC) in Japan.

Aim

To compare the real‐world efficacy and safety of these three JAK inhibitors in UC.

Methods

This was a multicentre, retrospective study of patients with UC started on JAK inhibitors. The primary outcome was clinical remission at 10, 26 and 58 weeks, and at the most recent follow‐up. To compare the efficacy and safety among the JAK inhibitors, we created three matched cohorts (upadacitinib vs. filgotinib, tofacitinib vs. filgotinib and upadacitinib vs. tofacitinib) using propensity score matching.

Results

We identified 228 upadacitinib‐treated patients (median follow‐up 49 weeks; IQR 25–72), 215 filgotinib‐treated patients (follow‐up 56 weeks; IQR 17–82) and 159 tofacitinib‐treated patients (follow‐up 112 weeks; IQR 10–258). Clinical remission rates for upadacitinib, filgotinib and tofacitinib at the most recent follow‐up were 72.8%, 50.6% and 45.8%, respectively. Over 70% of the patients previously treated with other biologics or JAK inhibitors achieved clinical remission with upadacitinib. On multivariate analysis, the number of previous advanced therapies was inversely associated with the efficacy of filgotinib and tofacitinib. Comparative analysis showed that upadacitinib‐treated patients had higher efficacy and lower risk of discontinuation than patients treated with other JAK inhibitors. However, upadacitinib had a significant risk of acne.

Conclusions

Considering the particularly high efficacy of upadacitinib, even in patients with refractory UC, filgotinib or tofacitinib may be considered as an upfront JAK inhibitor before using upadacitinib.

Subjects

MeSH terms (MEDLINE)

Colitis, UlcerativeJanus Kinase InhibitorsPiperidinesPyrimidinesPyrrolesHumansFemaleMaleRetrospective StudiesAdultJapanMiddle AgedTreatment OutcomeHeterocyclic Compounds, 3-RingRemission InductionTriazolesAgedBenzamidesPropensity ScorePyridines

Author keywords

Janus kinasefilgotinibtofacitinibulcerative colitisupadacitinib

Substances

Janus Kinase InhibitorsupadacitinibPiperidinestofacitinibPyrimidinesGLPG0634PyrrolesHeterocyclic Compounds, 3-RingTriazolesBenzamides

Authors and institutions

  • Department of Gastroenterology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
  • Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan.
  • Department of Gastroenterology, Kitasato University School of Medicine, Kanagawa, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan.
  • Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.

ORCID profiles: Shintaro Akiyama, Toshiyuki Sakurai, Shunichi Yanai, Masayuki Saruta, Toshimitsu Fujii

Cite

APA

Akiyama, S., Shimizu, H., Tamura, A., Yokoyama, K., Sakurai, T., Kobayashi, M., Eizuka, M., Yanai, S., Nomura, K., Shibuya, T., Takahara, M., Hiraoka, S., Sako, M., Yoshida, A., Tsuruta, K., Yoshioka, S., Koroku, M., Omori, T., Saruta, M., …, & Fujii, T. (2025). Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan. Alimentary Pharmacology & Therapeutics, 61(3), 524-537. https://doi.org/10.1111/apt.18406

Vancouver

Akiyama S, Shimizu H, Tamura A, Yokoyama K, Sakurai T, Kobayashi M, et al. Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan. Alimentary Pharmacology & Therapeutics. 2025;61(3):524-537. doi:10.1111/apt.18406

BibTeX
@article{Akiyama2025,
  author = {Akiyama, Shintaro and Shimizu, Hiromichi and Tamura, Akiko and Yokoyama, Kaoru and Sakurai, Toshiyuki and Kobayashi, Mariko and Eizuka, Makoto and Yanai, Shunichi and Nomura, Kei and Shibuya, Tomoyoshi and Takahara, Masahiro and Hiraoka, Sakiko and Sako, Minako and Yoshida, Atsushi and Tsuruta, Kozo and Yoshioka, Shinichiro and Koroku, Miki and Omori, Teppei and Saruta, Masayuki and Matsumoto, Takayuki and Okamoto, Ryuichi and Tsuchiya, Kiichiro and Fujii, Toshimitsu},
  title = {Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {3},
  pages = {524--537},
  doi = {10.1111/apt.18406}
}
Start for free →